Share >  
Share
Share on Tumblr

Fortis Clinical Research Ltd

News »

   latest by relevance
CRISIL assigns valuation grade of 5/5 to Fortis Healthcare
Sep 26, 2011 at 11:32 | Source: Moneycontrol.com
CRISIL Research has come out with its report on Fortis Healthcare (India) Ltd. The research firm has maintained fundamental grade of 4/5 to the company and assigned the fair value of Rs 185 per share in its September 23, 2011 report.
CRISIL assigns fundamental grade 4/5 to Fortis Health
Jul 15, 2011 at 17:14 | Source: Moneycontrol.com
CRISIL Research has come out with its report on Fortis Healthcare (India) Ltd. The research firm has assigned a CRISIL IER fundamental grade of "4/5" to the company and maintained the fair value of Rs 185 per share, in its July 15, 2011 report.
Fortis Healthcare to manage hospital in Haryana
Dec 30, 2009 at 16:19 | Source: Reuters
Hospital chain Fortis Healthcare Ltd said on Wednesday it will manage a 175-bed hospital in Haryana, widening its presence in that part of the country.
Fortis not talking to Asiri; Srilanka not priority: Source
Dec 10, 2009 at 15:07 | Source: Reuters
Fortis Healthcare Ltd on Thursday said it is not in talks with Sri Lanka's Asiri Hospitals to buy clinics there and a senior official said the island nation is not a priority.
Jubilant enters research collaboration with AstraZeneca
May 05, 2009 at 19:14 | Source: press release
Jubilant Organosys Ltd announced that its Bangalore, India, based subsidiary, Jubilant Biosys Ltd, has signed a research collaboration agreement with, AstraZeneca, and focused on delivering novel drug candidates into the international pharmaceutical company's pre-clinical pipeline.
Clinsys Clinical Research buys TrialStat ClinicalAnalytics
Nov 22, 2008 at 11:55
Jubilant Organosys Ltd. announced today that its subsidiary, Clinsys Clinical Research, Inc., New Jersey, USA, a global contract research organization (CRO), has acquired TrialStat ClinicalAnalytics from TrialStat for a purchase consideration of CAD 750,000

Videos »
Ranbaxy demerger: Co to save $25 m in costs
more »

Photos »

  /  
Related News »
Juventas Therapeutics Enrolling Patients in Phase IIa STOP-CLI Clinical Trial
Elcock Professor of Surgical Research at the Northwestern University School of Medicine. "CLI is a devastating disease for which there are no good therapeutic options. JVS-100 is a regenerative therapy with the potential to improve clinical ...
May 14, 2012 at 23:55 | Source: Phramalive.com

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window